Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Date set for FDA panel on drug-eluting stents

This article was originally published in Clinica

Executive Summary

The US FDA will announce tomorrow that it has scheduled an advisory panel meeting on December 7-8 to discuss recent studies that have shown a small, but significant, increase in the rate of death and heart attack due to blood clots linked to drug-eluting stents (DES).

You may also be interested in...



Novartis In Line For Ofatumumab MS Approval In June

Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.

ICER Partnering With Aetion To Scale Up Use Of RWE In Value Assessments

Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.

‘Highly Questionable’ GMP Compliance In Pakistan Prompts New Licensing System

Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.

Topics

UsernamePublicRestriction

Register

MT053257

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel